Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action

Elekta Introduces Next Generation MEG System for Monitoring the Brain in
Action

New Elekta Neuromag TRIUX platform boosts robustness and ease of use to
improve understanding of brain function and disorders

BARCELONA, June 7, 2010 /PRNewswire/ - At the Organization of Human
Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10),
Elekta unveiled its next generation magnetoencephalography (MEG) system,
Elekta Neuromag® TRIUX*. A platform that addresses key requirements
critical for monitoring normal and abnormal brain activity, Elekta
Neuromag TRIUX was designed to operate in virtually any clinical
environment—an advance welcomed by the growing number of Elekta Neuromag
clinical and research facilities worldwide.

More robust, patient-friendly and easier to use
Implementing a MEG program will be more practical for most clinical
environments with the Elekta Neuromag TRIUX system's dynamic range,
which has been increased three-fold, in addition to built-in active
shielding, which protects its ultrasensitive sensor array from magnetic
interference. These improvements make Elekta Neuromag TRIUX suitable for
siting in even the busiest hospitals and research centers, and further
demonstrate Elekta's commitment to helping centers adopt this innovative
technology. 

Elekta Neuromag TRIUX also provides several features designed to
simplify day-to-day use of the system and enhance patient experience.
These include a new connector panel—with easy to access connectors—and
an all-new gantry that allows clinicians and researchers to conduct MEG
measurements with the patient in a more comfortable upright position. 

In addition, Elekta Neuromag TRIUX is undergoing a major revision to its
system software to perfect acquisition workflows and routine quality
assurance procedures. 

“This system is now the definitive platform from which to launch MEG
programs now and far into the future. In fact, many upcoming
improvements and options presently in development may be ordered already
today to ensure Elekta Neuromag TRIUX will be continually updated with
releases as they become available,” says Stephen Otto, Chairman of
Elekta's Neuromag Business. “Current users also will be pleased to
discover the time-proven triple sensor array remains unchanged to
maintain full compatibility with the wealth of research conducted by the
Neuromag user community.” 

What is MEG?
MEG is based on the detection of the very weak magnetic fields that
originate from electrical activity within the brain. These signals are
detected with a SQUID (superconducting quantum interference device)
array placed close to the scalp.

MEG functional mapping has proven clinically useful to evaluate epilepsy
and to perform presurgical mapping of visual, auditory, somatosensory,
motor cortex and language functional areas. MEG is used to localize both
epileptic activity between seizures and important healthy tissues in the
cortex that must be preserved during surgery. Accurate localization of
cortical tissues also is useful when performing other types of surgery,
such as tumor removal. In addition, MEG can be used to assist in the
placement of intracranial electrodes. 

There are numerous MEG research applications. These include the neural
basis of developmental disorders, as well as psychiatric and
neurodegenerative diseases. Investigators also are using MEG to address
basic questions about brain functions, such as memory, attention,
emotion, language and social cognition, abilities that are frequently
disrupted by brain disorders. 

Elekta Neuromag TRIUX will be available as a turn-key system or as a
hardware / software upgrade for certain Elekta Neuromag models. To learn
more, visit www.elekta.com/MEG (http://www.elekta.com/MEG). 

*Elekta Neuromag® TRIUX is a works in progress. Specifications and
product details subject to change without notice.  

# # # 

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
stina.thorman@elekta.com (stina.thorman@elekta.com)
Time zone: CET: Central European 

Michelle Lee, Director, Global Public Relations and Brand Management,
Elekta
Tel: +1 770-670-2447, email:
michelle.lee@elekta.com (michelle.lee@elekta.com)
Time zone: EDT: Eastern Daylight 

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy and radiosurgery, as well as workflow
enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients
receive diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate
headquarter is located in Stockholm, Sweden, and the company is listed
on the Nordic Exchange under the ticker EKTAb. For more information
about Elekta, please visit www.elekta.com (http://www.elekta.com/).